News & Updates

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

11/24/2020

Excerpt from the Press Release: SAN RAFAEL, Calif. and TORONTO, Nov. 17, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications…

Read More

The FDA’s Digital Health Center Of Excellence: Why It Matters And What It Means To You

11/23/2020

Excerpt from the Article: Last month, the US Food and Drug Administration (FDA) launched the Digital Health Center of Excellence (DHCoE), bolstering the shift toward digital that the healthcare industry has already been embracing. Investment in digital health is at an all-time high. The market cap created from nine IPOs in 2019 from companies in…

Read More

AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

11/23/2020

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis, further reinforcing the potential of ex vivo lentiviral…

Read More

NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy

11/22/2020

Excerpt from the Press Release: PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–NANOBOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo pre-clinical data from two (2) studies at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting. One…

Read More

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

11/21/2020

Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 13, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with Critical…

Read More

SCOPE International US office celebrates 5th Anniversary

11/20/2020

Excerpt from the company announcement: “This summer, the US office of SCOPE International celebrated our 5th Anniversary. There are many words that can be used to describe the journey thus far, but ones that stick out include: Engaging, Challenging, Rewarding, Collaborative, and Family. A big thank you to our partners, clients and each of the…

Read More

Ask Us Anything – Medical Devices and Diagnostics

11/19/2020

Yesterday, we held our fifth virtual networking meeting in our ongoing series called Ask us Anything In Clinical Research. For our fifth meeting we covered the topic of Medical Device and Diagnostic studies. Our guest for this meeting was Eric Filion, Vice President of Sales for LOK North America – Medical Device Regulatory experts. Thank…

Read More

Hope Biosciences Stem Cell Research Foundation Selects Phlexglobal to Support Rapid, Compliant Investigational New Drug Application for COVID-19 Therapy

11/19/2020

Excerpt from the Press Release: Phlexglobal, a leading innovative technology and services provider for the life sciences industry, today announces that Hope Biosciences Stem Cell Research Foundation has selected Phlexglobal’s advanced SaaS solution, PhlexSubmission, to enhance the efficiency and quality of its eCTD submissions process. As an organization dedicated to advancing research through innovative protocols…

Read More

Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer

11/18/2020

Excerpt from the Press Release: CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ — Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced the appointment of Randi Isaacs, M.D., as Chief Medical Officer. Dr. Isaacs brings to the Werewolf team more than 20 years’ experience as a hematologist and oncologist driving clinical…

Read More

Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2

11/17/2020

Excerpt from the Press Release: SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers. Sorrento has previously…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives